103_CD
Alliance_NN
UniChem_NN
Plc_NN
42_CD
ACQUISITIONS_NOMZ
CONTINUED_VBD
Purchase_NN
of_PIN
businesses_NOMZ
continued_VBD
Retail_NN
Book_NN
Provisional_NN
value_NN
at_PIN
Fair_NN
value_NN
fair_JJ
value_NN
at_PIN
acquisition_NOMZ
adjustments_NOMZ
acquisition_NOMZ
Assets_NN
acquired_VBN [WZPAST]
at_PIN
book_NN
and_CC
provisional_JJ
fair_JJ
value_NN
million_CD
million_CD
million_CD
Intangible_JJ
assets_NN
retail_JJ
pharmacy_NN
licences_VPRT
24.7_CD
69.2_CD
93.9_CD
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
6.7_CD
0.2_CD
6.5_CD
Inventories_NN
11.2_CD
0.5_CD
10.7_CD
Trade_NN
and_CC
other_JJ
receivables_NN
9.2_CD
0.2_CD
9.4_CD
Borrowings_GER
bank_NN
overdrafts_NN
2.5_CD
2.5_CD
bank_NN
loans_NN
2.5_CD
2.5_CD
Trade_NN
and_CC
other_JJ
payables_NN
10.7_CD
10.7_CD
Current_JJ
corporate_JJ
tax_NN
liabilities_NOMZ
3.3_CD
0.1_CD
3.4_CD
Deferred_JJ
tax_NN
liabilities_NOMZ
20.6_CD
20.6_CD
Net_JJ
assets_NN
acquired_VBN
32.8_CD
48.0_CD
80.8_CD
Consideration_NOMZ
paid_VBD
million_CD
Cash_NN
117.3_CD
Deferred_JJ
consideration_NOMZ
movement_NOMZ
0.3_CD
117.0_CD
Purchased_VBN
goodwill_NN
36.2_CD
Retail_NN
acquisitions_NOMZ
comprised_VBD
the_DT
acquisition_NOMZ
of_PIN
83_CD
pharmacies_NN
in_PIN
the_DT
UK_NN
,_,
Norway_NN
and_CC
The_DT
Netherlands_NN
._.
43_CD
DISPOSALS_NN
Disposal_NN
of_PIN
businesses_NOMZ
During_PIN
the_DT
year_NN
the_DT
Group_NN
disposed_VBD
of_PIN
51_CD
%_NN
of_PIN
its_PIT
interest_NN
in_PIN
Alliance_NN
UniChem_NN
Farmacutica_NN
A._NN
G._NN
its_PIT
entire_JJ
interest_NN
in_PIN
Elvetec_NN
in_PIN
France_NN
and_CC
a_DT
number_NN
of_PIN
other_JJ
minor_JJ
interests_NN
._.
The_DT
proceeds_NN
received_VBD
for_PIN
these_DEMO
transactions_NOMZ
were_VBD [BEMA]
32.5_CD
million_CD
._.
Within_PIN
the_DT
balance_NN
sheets_NN
of_PIN
the_DT
businesses_NOMZ
disposed_VBN [WZPAST]
were_VBD [BEMA]
net_JJ
overdrafts_NN
of_PIN
66.2_CD
million_CD
._.
In_CONJ
addition_NULL
,_,
the_DT
Group_NN
received_VBD
deferred_VBN
consideration_NOMZ
of_PIN
12.0_CD
million_CD
arising_VBG
from_PIN
the_DT
disposal_NN
of_PIN
non-core_JJ
UK_NN
businesses_NOMZ
in_PIN
2004_CD
._.
Disposal_NN
of_PIN
investments_NOMZ
in_PIN
associates_NN
As_IN
described_VBN
in_PIN
note_NN
42_CD
,_,
during_PIN
the_DT
year_NN
the_DT
Group_NN
restructured_VBD
its_PIT
relationship_NN
with_PIN
Galenica_NN
A._NN
G._NN
._.
The_DT
transaction_NOMZ
was_VBD [PASS]
settled_VBN
on_PIN
a_DT
net_JJ
basis_NN
and_CC
resulted_VBD
in_PIN
a_DT
net_JJ
cash_NN
inflow_NN
to_PIN
the_DT
Group_NN
of_PIN
15.7_CD
million_CD
._.
This_DEMP
comprised_VBN
8.6_CD
million_CD
of_PIN
net_JJ
proceeds_NN
,_,
41.4_CD
million_CD
of_PIN
associate_JJ
loans_NN
being_VBG [WZPRES] [PASS]
repaid_VBN
and_CC
,_,
in_PIN
respect_NN
of_PIN
the_DT
acquired_VBN
companies_NN
,_,
2.0_CD
million_CD
of_PIN
net_JJ
cash_NN
and_CC
36.3_CD
million_CD
of_PIN
borrowings_GER
were_VBD [PASS]
held_VBN [PRIV]
in_PIN
the_DT
acquired_VBN
balance_NN
sheets_NN
._.
In_CONJ
addition_NULL
,_,
the_DT
Group_NN
disposed_VBD
of_PIN
a_DT
minor_JJ
associated_VBN
undertaking_GER
for_PIN
disposal_NN
proceeds_NN
of_PIN
0.1_CD
million_CD
._.
Disposal_NN
of_PIN
available-for-sale_JJ
investments_NOMZ
During_PIN
the_DT
first_JJ
half_NN
of_PIN
the_DT
year_NN
,_,
the_DT
Group_NN
disposed_VBD
of_PIN
its_PIT
investment_NOMZ
in_PIN
Sanacorp_NN
Pharmahandel_NN
A._NN
G._NN
._.
44_CD
SHARE-BASED_JJ
PAYMENTS_NOMZ
The_DT
Group_NN
issues_NN
equity_NOMZ
settled_VBD
,_,
share-based_JJ
payments_NOMZ
to_PIN
certain_JJ
employees_NN
._.
Equity_NOMZ
settled_VBD
share-based_JJ
payments_NOMZ
are_VPRT [PASS]
measured_VBN
at_PIN
fair_JJ
value_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
The_DT
fair_JJ
value_NN
determined_VBN [SUAV] [PRIV] [WZPAST]
at_PIN
the_DT
grant_NN
date_NN
of_PIN
the_DT
equity_NOMZ
settled_VBD
,_,
share-based_JJ
payments_NOMZ
is_VPRT [PASS]
expensed_VBN
on_PIN
a_DT
straight-line_JJ
basis_NN
over_IN
the_DT
vesting_JJ
period_NN
,_,
based_VBN [PASTP]
on_PIN
the_DT
Groups_NN
estimate_NN
of_PIN
shares_NN
that_TSUB
will_PRMD
eventually_TIME
vest_NN
._.
Fair_NN
value_NN
is_VPRT [BYPA]
measured_VBN
by_PIN
use_NN
of_PIN
an_DT
actuarial_JJ
binomial_JJ
model_NN
._.
The_DT
model_NN
includes_VPRT
adjustments_NOMZ
,_,
based_VBN [PASTP]
on_PIN
managements_NOMZ
best_JJ
estimate_NN
,_,
for_PIN
the_DT
effects_NN
of_PIN
exercise_NN
restrictions_NOMZ
,_,
behavioural_JJ
considerations_NOMZ
and_CC
expected_VBN [PRIV]
dividend_NN
payments_NOMZ
._.
The_DT
option_NOMZ
life_NN
is_VPRT [BYPA]
derived_VBN
by_PIN
the_DT
model_NN
based_VBN [WZPAST]
on_PIN
these_DEMO
assumptions_NOMZ
and_CC
the_DT
other_JJ
assumptions_NOMZ
identified_VBN
below_PLACE
._.
The_DT
total_JJ
expense_NN
included_VBD
within_PIN
profit_NN
from_PIN
operations_NOMZ
in_PIN
respect_NN
of_PIN
share-based_JJ
payments_NOMZ
was_VBD [BEMA]
5.3_CD
million_CD
2004_CD
2.2_CD
million_CD
._.
